ASX - By Stock
|
SDL |
Re:
2nd Anniversary of.......Nothing.!!
|
|
Baremoney
|
65 |
27K |
4 |
09/09/20 |
09/09/20 |
ASX - By Stock
|
65
|
27K
|
4
|
|
ASX - By Stock
|
PER |
Re:
Ann: ANP Submits US Orphan Drug application for ATL1102 in DMD
|
|
Baremoney
|
60 |
21K |
0 |
24/08/20 |
24/08/20 |
ASX - By Stock
|
60
|
21K
|
0
|
|
ASX - By Stock
|
PER |
Re:
An FDA Act that may be relvant to ATL-1102 FDA
|
|
Baremoney
|
210 |
61K |
1 |
12/08/20 |
12/08/20 |
ASX - By Stock
|
210
|
61K
|
1
|
|
ASX - By Stock
|
PER |
Re:
An FDA Act that may be relvant to ATL-1102 FDA
|
|
Baremoney
|
210 |
61K |
2 |
10/08/20 |
10/08/20 |
ASX - By Stock
|
210
|
61K
|
2
|
|
ASX - By Stock
|
PER |
Re:
An FDA Act that may be relvant to ATL-1102 FDA
|
|
Baremoney
|
210 |
61K |
13 |
08/08/20 |
08/08/20 |
ASX - By Stock
|
210
|
61K
|
13
|
|
ASX - By Stock
|
PER |
Re:
Antisense Presenting At Biotech Webinar (4 Aug)
|
|
Baremoney
|
44 |
14K |
0 |
04/08/20 |
04/08/20 |
ASX - By Stock
|
44
|
14K
|
0
|
|
ASX - By Stock
|
PER |
Re:
Ann: ANP Submits US Orphan Drug application for ATL1102 in DMD
|
|
Baremoney
|
60 |
21K |
0 |
04/08/20 |
04/08/20 |
ASX - By Stock
|
60
|
21K
|
0
|
|
ASX - By Stock
|
PER |
Re:
Prof Thomas Voit, DMD expert, interview with Wilsons advisory
|
|
Baremoney
|
47 |
15K |
2 |
09/07/20 |
09/07/20 |
ASX - By Stock
|
47
|
15K
|
2
|
|
ASX - By Stock
|
PER |
Re:
Prof Thomas Voit, DMD expert, interview with Wilsons advisory
|
|
Baremoney
|
47 |
15K |
2 |
09/07/20 |
09/07/20 |
ASX - By Stock
|
47
|
15K
|
2
|
|
ASX - By Stock
|
PER |
Re:
Prof Thomas Voit, DMD expert, interview with Wilsons advisory
|
|
Baremoney
|
47 |
15K |
18 |
09/07/20 |
09/07/20 |
ASX - By Stock
|
47
|
15K
|
18
|
|
ASX - By Stock
|
PER |
Re:
Asian investors are targeting Aussie stocks
|
|
Baremoney
|
18 |
5.9K |
4 |
09/07/20 |
09/07/20 |
ASX - By Stock
|
18
|
5.9K
|
4
|
|
Charts
|
PER |
Re:
Chart
|
|
Baremoney
|
5.9K |
2.3M |
7 |
08/07/20 |
08/07/20 |
Charts
|
5.9K
|
2.3M
|
7
|
|
Charts
|
PER |
Re:
Chart
|
|
Baremoney
|
5.9K |
2.3M |
4 |
08/07/20 |
08/07/20 |
Charts
|
5.9K
|
2.3M
|
4
|
|
ASX - By Stock
|
PER |
Re:
Prof Thomas Voit, DMD expert, interview with Wilsons advisory
|
|
Baremoney
|
47 |
15K |
5 |
07/07/20 |
07/07/20 |
ASX - By Stock
|
47
|
15K
|
5
|
|
ASX - By Stock
|
PER |
Re:
Last webinar - EMA
|
|
Baremoney
|
8 |
1.5K |
2 |
01/07/20 |
01/07/20 |
ASX - By Stock
|
8
|
1.5K
|
2
|
|
ASX - By Stock
|
PER |
Re:
Last webinar - EMA
|
|
Baremoney
|
8 |
1.5K |
2 |
01/07/20 |
01/07/20 |
ASX - By Stock
|
8
|
1.5K
|
2
|
|
ASX - By Stock
|
PER |
Re:
Last trial before Anp can market their DMD drug in Europe
|
|
Baremoney
|
22 |
6.6K |
1 |
28/06/20 |
28/06/20 |
ASX - By Stock
|
22
|
6.6K
|
1
|
|
ASX - By Stock
|
PER |
Re:
Last trial before Anp can market their DMD drug in Europe
|
|
Baremoney
|
22 |
6.6K |
3 |
27/06/20 |
27/06/20 |
ASX - By Stock
|
22
|
6.6K
|
3
|
|
ASX - By Stock
|
PER |
Re:
Capricor Therapeutics
|
|
Baremoney
|
49 |
11K |
0 |
22/06/20 |
22/06/20 |
ASX - By Stock
|
49
|
11K
|
0
|
|
ASX - By Stock
|
PER |
Re:
PPMD webinar
|
|
Baremoney
|
72 |
19K |
0 |
21/06/20 |
21/06/20 |
ASX - By Stock
|
72
|
19K
|
0
|
|
ASX - By Stock
|
PER |
Re:
Ann: Quarterly Update and Appendix 4C
|
|
Baremoney
|
40 |
13K |
4 |
21/04/20 |
21/04/20 |
ASX - By Stock
|
40
|
13K
|
4
|
|
ASX - By Stock
|
PER |
Re:
Ann: Quarterly Update and Appendix 4C
|
|
Baremoney
|
40 |
13K |
2 |
21/04/20 |
21/04/20 |
ASX - By Stock
|
40
|
13K
|
2
|
|
ASX - By Stock
|
PER |
Re:
Ann: Phase II DMD trial database lock and final results on track
|
|
Baremoney
|
96 |
34K |
4 |
21/04/20 |
21/04/20 |
ASX - By Stock
|
96
|
34K
|
4
|
|
ASX - By Stock
|
PER |
Re:
Ann: Phase II DMD trial database lock and final results on track
|
|
Baremoney
|
96 |
34K |
1 |
20/03/20 |
20/03/20 |
ASX - By Stock
|
96
|
34K
|
1
|
|
ASX - By Stock
|
PER |
Re:
Ann: Phase II DMD trial database lock and final results on track
|
|
Baremoney
|
96 |
34K |
2 |
20/03/20 |
20/03/20 |
ASX - By Stock
|
96
|
34K
|
2
|
|
Charts
|
PER |
Re:
Chart
|
|
Baremoney
|
5.9K |
2.3M |
9 |
14/02/20 |
14/02/20 |
Charts
|
5.9K
|
2.3M
|
9
|
|
ASX - By Stock
|
PGM |
Re:
Share price up 35%
|
|
Baremoney
|
5 |
2.9K |
1 |
21/01/20 |
21/01/20 |
ASX - By Stock
|
5
|
2.9K
|
1
|
|
ASX - By Stock
|
PER |
Re:
Ann: Change of Director's Interest Notice (RM)
|
|
Baremoney
|
9 |
5.1K |
1 |
19/12/19 |
19/12/19 |
ASX - By Stock
|
9
|
5.1K
|
1
|
|
ASX - By Stock
|
PER |
Re:
Ann: Change of Director's Interest Notice (MD)
|
|
Baremoney
|
5 |
3.8K |
1 |
18/12/19 |
18/12/19 |
ASX - By Stock
|
5
|
3.8K
|
1
|
|
Charts
|
PER |
Re:
Chart
|
|
Baremoney
|
5.9K |
2.3M |
5 |
06/12/19 |
06/12/19 |
Charts
|
5.9K
|
2.3M
|
5
|
|
ASX - By Stock
|
PER |
Re:
ATL1102 Blockbuster drug
|
|
Baremoney
|
58 |
30K |
1 |
22/10/19 |
22/10/19 |
ASX - By Stock
|
58
|
30K
|
1
|
|
ASX - By Stock
|
PER |
Re:
ATL1102 Blockbuster drug
|
|
Baremoney
|
58 |
30K |
2 |
22/10/19 |
22/10/19 |
ASX - By Stock
|
58
|
30K
|
2
|
|
ASX - By Stock
|
PER |
Re:
ATL1102 Blockbuster drug
|
|
Baremoney
|
58 |
30K |
1 |
22/10/19 |
22/10/19 |
ASX - By Stock
|
58
|
30K
|
1
|
|
Charts
|
PER |
Re:
TechKnow Investor Roadshow
|
|
Baremoney
|
47 |
22K |
8 |
15/10/19 |
15/10/19 |
Charts
|
47
|
22K
|
8
|
|
ASX - By Stock
|
PER |
Re:
Ann: Positive preliminary results from ATL1102 DMD Phase II trial
|
|
Baremoney
|
595 |
346K |
4 |
07/10/19 |
07/10/19 |
ASX - By Stock
|
595
|
346K
|
4
|
|
ASX - By Stock
|
PER |
Re:
Ann: Positive preliminary results from ATL1102 DMD Phase II trial
|
|
Baremoney
|
595 |
346K |
1 |
02/10/19 |
02/10/19 |
ASX - By Stock
|
595
|
346K
|
1
|
|